MRC Clinical Trials Unit at UCL
@mrcctu.bsky.social
We carry out innovative #ClinicalTrials and develop new #Methodology that has global impact, improving health worldwide.
#MedSky #StatsSky
#MedSky #StatsSky
Pinned
Shorter, more intensive treatment for TB meningitis in children is not as effective as the standard treatment | MRC Clinical Trials Unit at UCL
19 Nov 2025
buff.ly
📈 New results from the SURE trial at #UnionConf
SURE showed that, for children living with TB meningitis, a short, intensive treatment is not as good as the standard treatment in preventing death or severe disability. Adding high-dose aspirin also showed no benefit.
🔗 Read more:
SURE showed that, for children living with TB meningitis, a short, intensive treatment is not as good as the standard treatment in preventing death or severe disability. Adding high-dose aspirin also showed no benefit.
🔗 Read more:
📰 Excited to see our NeoSep1 trial in @theguardian.com today!
NeoSep1 aims to find new antibiotic combinations for newborns with sepsis using our novel PRACTical design.
🔗 Read the full article here: www.theguardian.com/global-devel...
NeoSep1 aims to find new antibiotic combinations for newborns with sepsis using our novel PRACTical design.
🔗 Read the full article here: www.theguardian.com/global-devel...
Antibiotic resistance: how a pioneering trial is using old drugs to save babies from sepsis
The infection is responsible for 800,000 newborn deaths each year, but clinics in eight countries are working together to find new treatments
www.theguardian.com
November 25, 2025 at 4:59 PM
📰 Excited to see our NeoSep1 trial in @theguardian.com today!
NeoSep1 aims to find new antibiotic combinations for newborns with sepsis using our novel PRACTical design.
🔗 Read the full article here: www.theguardian.com/global-devel...
NeoSep1 aims to find new antibiotic combinations for newborns with sepsis using our novel PRACTical design.
🔗 Read the full article here: www.theguardian.com/global-devel...
📝New guidance on data retention and re-use!
We’re proud to have contributed to this resource alongside leading experts in the field.
This guidance helps ensure responsible data management, compliance, and opportunities for data re-use, supporting transparency and research integrity across trials.
We’re proud to have contributed to this resource alongside leading experts in the field.
This guidance helps ensure responsible data management, compliance, and opportunities for data re-use, supporting transparency and research integrity across trials.
November 25, 2025 at 10:02 AM
📝New guidance on data retention and re-use!
We’re proud to have contributed to this resource alongside leading experts in the field.
This guidance helps ensure responsible data management, compliance, and opportunities for data re-use, supporting transparency and research integrity across trials.
We’re proud to have contributed to this resource alongside leading experts in the field.
This guidance helps ensure responsible data management, compliance, and opportunities for data re-use, supporting transparency and research integrity across trials.
This week is World Antimicrobial Resistance Awareness Week #WAAW2025, a time to raise awareness & encourage action to reduce the #AMR crisis.
We are fighting the rise of AMR through our #ClinicalTrials.
Find out how our current research is making a difference in this thread 🧵
We are fighting the rise of AMR through our #ClinicalTrials.
Find out how our current research is making a difference in this thread 🧵
November 20, 2025 at 8:56 AM
This week is World Antimicrobial Resistance Awareness Week #WAAW2025, a time to raise awareness & encourage action to reduce the #AMR crisis.
We are fighting the rise of AMR through our #ClinicalTrials.
Find out how our current research is making a difference in this thread 🧵
We are fighting the rise of AMR through our #ClinicalTrials.
Find out how our current research is making a difference in this thread 🧵
📈 New results from the SURE trial at #UnionConf
SURE showed that, for children living with TB meningitis, a short, intensive treatment is not as good as the standard treatment in preventing death or severe disability. Adding high-dose aspirin also showed no benefit.
🔗 Read more:
SURE showed that, for children living with TB meningitis, a short, intensive treatment is not as good as the standard treatment in preventing death or severe disability. Adding high-dose aspirin also showed no benefit.
🔗 Read more:
Shorter, more intensive treatment for TB meningitis in children is not as effective as the standard treatment | MRC Clinical Trials Unit at UCL
19 Nov 2025
buff.ly
November 19, 2025 at 4:08 PM
📈 New results from the SURE trial at #UnionConf
SURE showed that, for children living with TB meningitis, a short, intensive treatment is not as good as the standard treatment in preventing death or severe disability. Adding high-dose aspirin also showed no benefit.
🔗 Read more:
SURE showed that, for children living with TB meningitis, a short, intensive treatment is not as good as the standard treatment in preventing death or severe disability. Adding high-dose aspirin also showed no benefit.
🔗 Read more:
It’s Wednesday, time to share what we’re #ProudestOf!
Today, we celebrate Elena Frangou, one of our Senior Research Fellows and one of the statisticians in the RAMPART #ClinicalTrial.
We asked Elena what she’s #ProudestOf in her work at the Unit 👇
Today, we celebrate Elena Frangou, one of our Senior Research Fellows and one of the statisticians in the RAMPART #ClinicalTrial.
We asked Elena what she’s #ProudestOf in her work at the Unit 👇
November 19, 2025 at 8:59 AM
It’s Wednesday, time to share what we’re #ProudestOf!
Today, we celebrate Elena Frangou, one of our Senior Research Fellows and one of the statisticians in the RAMPART #ClinicalTrial.
We asked Elena what she’s #ProudestOf in her work at the Unit 👇
Today, we celebrate Elena Frangou, one of our Senior Research Fellows and one of the statisticians in the RAMPART #ClinicalTrial.
We asked Elena what she’s #ProudestOf in her work at the Unit 👇
📝 New guidance on improving the use of inverse probability of censoring weighting (IPCW) method in #ClinicalTrials.
The paper explains how to apply IPCW effectively and how to stabilise IPCW weights to improve precision, without overlooking potential bias.
🔗 Read more about it:
The paper explains how to apply IPCW effectively and how to stabilise IPCW weights to improve precision, without overlooking potential bias.
🔗 Read more about it:
New methodology guidance on inverse probability of censoring weighting in clinical trials | MRC Clinical Trials Unit at UCL
18 Nov 2025
buff.ly
November 18, 2025 at 9:10 AM
📝 New guidance on improving the use of inverse probability of censoring weighting (IPCW) method in #ClinicalTrials.
The paper explains how to apply IPCW effectively and how to stabilise IPCW weights to improve precision, without overlooking potential bias.
🔗 Read more about it:
The paper explains how to apply IPCW effectively and how to stabilise IPCW weights to improve precision, without overlooking potential bias.
🔗 Read more about it:
#UnionConf2025 starts tomorrow! Our researchers and collaborators will showcase their latest #tuberculosis #TB research, including new findings from the SURE trial in TB meningitis in children.
Check out our schedule of presentations.
🔗 www.mrcctu.ucl.ac.uk/news/news-st...
Check out our schedule of presentations.
🔗 www.mrcctu.ucl.ac.uk/news/news-st...
November 17, 2025 at 9:46 AM
#UnionConf2025 starts tomorrow! Our researchers and collaborators will showcase their latest #tuberculosis #TB research, including new findings from the SURE trial in TB meningitis in children.
Check out our schedule of presentations.
🔗 www.mrcctu.ucl.ac.uk/news/news-st...
Check out our schedule of presentations.
🔗 www.mrcctu.ucl.ac.uk/news/news-st...
#ProstateCancer is the most common cancer among men in the UK. This #Movember, discover how our PROMIS study helped improve prostate cancer diagnosis, sparing thousands of men unnecessary biopsies.
📽️ More in this short video from our 25 at 25 anniversary series: www.youtube.com/watch?v=CcP3...
📽️ More in this short video from our 25 at 25 anniversary series: www.youtube.com/watch?v=CcP3...
25 at 25: Improving prostate cancer diagnosis
YouTube video by MRC Clinical Trials Unit at UCL
www.youtube.com
November 13, 2025 at 3:52 PM
#ProstateCancer is the most common cancer among men in the UK. This #Movember, discover how our PROMIS study helped improve prostate cancer diagnosis, sparing thousands of men unnecessary biopsies.
📽️ More in this short video from our 25 at 25 anniversary series: www.youtube.com/watch?v=CcP3...
📽️ More in this short video from our 25 at 25 anniversary series: www.youtube.com/watch?v=CcP3...
Wednesday’s here, and so is our latest #ProudestOf moment!
This week, we’re celebrating Sharon Love, Associate Professor of Clinical Trial Conduct, who leads the methodology conduct work at the Unit.
We asked Sharon what she’s #ProudestOf in her work at the Unit 👇
This week, we’re celebrating Sharon Love, Associate Professor of Clinical Trial Conduct, who leads the methodology conduct work at the Unit.
We asked Sharon what she’s #ProudestOf in her work at the Unit 👇
November 12, 2025 at 8:52 AM
Wednesday’s here, and so is our latest #ProudestOf moment!
This week, we’re celebrating Sharon Love, Associate Professor of Clinical Trial Conduct, who leads the methodology conduct work at the Unit.
We asked Sharon what she’s #ProudestOf in her work at the Unit 👇
This week, we’re celebrating Sharon Love, Associate Professor of Clinical Trial Conduct, who leads the methodology conduct work at the Unit.
We asked Sharon what she’s #ProudestOf in her work at the Unit 👇
📺 Catch this short film on the ARCHERY study by LSHTM (@lshtm.bsky.social), where Dr. Ajay Aggarwal explores how AI could improve access to radiotherapy.
A powerful look at tech-driven solutions to global cancer care challenges.
🔗 www.youtube.com/watch?v=lTox...
#Radiotherapy #GlobalHealth
A powerful look at tech-driven solutions to global cancer care challenges.
🔗 www.youtube.com/watch?v=lTox...
#Radiotherapy #GlobalHealth
AI in Radiotherapy: A revolution in cancer care?
YouTube video by LSHTM
www.youtube.com
November 11, 2025 at 2:04 PM
📺 Catch this short film on the ARCHERY study by LSHTM (@lshtm.bsky.social), where Dr. Ajay Aggarwal explores how AI could improve access to radiotherapy.
A powerful look at tech-driven solutions to global cancer care challenges.
🔗 www.youtube.com/watch?v=lTox...
#Radiotherapy #GlobalHealth
A powerful look at tech-driven solutions to global cancer care challenges.
🔗 www.youtube.com/watch?v=lTox...
#Radiotherapy #GlobalHealth
Wednesday already? Let’s celebrate another #ProudestOf moment from our brilliant team at the Unit!
This week, we’re spotlighting Ilaria Motta, one of our passionate Principal Clinical Research Fellows working on tuberculosis #TB.
We asked Ilaria what she’s #ProudestOf in her work at the Unit👇
This week, we’re spotlighting Ilaria Motta, one of our passionate Principal Clinical Research Fellows working on tuberculosis #TB.
We asked Ilaria what she’s #ProudestOf in her work at the Unit👇
November 5, 2025 at 10:36 AM
Wednesday already? Let’s celebrate another #ProudestOf moment from our brilliant team at the Unit!
This week, we’re spotlighting Ilaria Motta, one of our passionate Principal Clinical Research Fellows working on tuberculosis #TB.
We asked Ilaria what she’s #ProudestOf in her work at the Unit👇
This week, we’re spotlighting Ilaria Motta, one of our passionate Principal Clinical Research Fellows working on tuberculosis #TB.
We asked Ilaria what she’s #ProudestOf in her work at the Unit👇
Nominations for the Brighter Future Award (BFA) are still open!
This international award, organised by Penta Foundation (@pentafoundation.bsky.social), celebrates individuals making a meaningful impact in maternal and child health.
⏳ New deadline: 11 Nov
🔗 Nominate your hero: penta-id.org/bfa/
This international award, organised by Penta Foundation (@pentafoundation.bsky.social), celebrates individuals making a meaningful impact in maternal and child health.
⏳ New deadline: 11 Nov
🔗 Nominate your hero: penta-id.org/bfa/
Incredible nominations are already coming in for #BFA2025 & we can’t wait to celebrate more champions.
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
November 4, 2025 at 11:16 AM
Nominations for the Brighter Future Award (BFA) are still open!
This international award, organised by Penta Foundation (@pentafoundation.bsky.social), celebrates individuals making a meaningful impact in maternal and child health.
⏳ New deadline: 11 Nov
🔗 Nominate your hero: penta-id.org/bfa/
This international award, organised by Penta Foundation (@pentafoundation.bsky.social), celebrates individuals making a meaningful impact in maternal and child health.
⏳ New deadline: 11 Nov
🔗 Nominate your hero: penta-id.org/bfa/
Dr Sophie Merrick (@drsophiemerrick.bsky.social) presented at #ESMO25 results from her qualitative study within the RAMPART #ClinicalTrial.
Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care.
🔗 View the poster: buff.ly/fPtvyZ2
Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care.
🔗 View the poster: buff.ly/fPtvyZ2
November 3, 2025 at 11:34 AM
Dr Sophie Merrick (@drsophiemerrick.bsky.social) presented at #ESMO25 results from her qualitative study within the RAMPART #ClinicalTrial.
Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care.
🔗 View the poster: buff.ly/fPtvyZ2
Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care.
🔗 View the poster: buff.ly/fPtvyZ2
Reposted by MRC Clinical Trials Unit at UCL
HRB-TMRN WEBINAR, with @mrcnihrtmrp.bsky.social - Prof. Max Parmar, Director of @mrcctu.bsky.social & UCL Institute of Clinical Trials, discusses 'Improving Health Faster: A more Strategic Approach to Randomised Trials & Meta-Analysis' on 20Nov@1pm(UTC): universityofgalway-ie.zoom.us/webinar/regi...
October 28, 2025 at 3:37 PM
HRB-TMRN WEBINAR, with @mrcnihrtmrp.bsky.social - Prof. Max Parmar, Director of @mrcctu.bsky.social & UCL Institute of Clinical Trials, discusses 'Improving Health Faster: A more Strategic Approach to Randomised Trials & Meta-Analysis' on 20Nov@1pm(UTC): universityofgalway-ie.zoom.us/webinar/regi...
It’s Wednesday, which means it’s time to celebrate another #ProudestOf moment from our amazing team at the Unit!
This week, we spotlight Tra My Pham, one of our dedicated senior Research Fellows working in analysis methodology.
We asked Tra what she’s #ProudestOf in her work at the Unit 👇
This week, we spotlight Tra My Pham, one of our dedicated senior Research Fellows working in analysis methodology.
We asked Tra what she’s #ProudestOf in her work at the Unit 👇
October 29, 2025 at 8:47 AM
It’s Wednesday, which means it’s time to celebrate another #ProudestOf moment from our amazing team at the Unit!
This week, we spotlight Tra My Pham, one of our dedicated senior Research Fellows working in analysis methodology.
We asked Tra what she’s #ProudestOf in her work at the Unit 👇
This week, we spotlight Tra My Pham, one of our dedicated senior Research Fellows working in analysis methodology.
We asked Tra what she’s #ProudestOf in her work at the Unit 👇
We're excited to share our latest work on estimands in clinical trials!
📄 Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands.
🔗 Read the full paper: journals.sagepub.com/doi/10.1177/...
📄 Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands.
🔗 Read the full paper: journals.sagepub.com/doi/10.1177/...
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 27, 2025 at 2:42 PM
We're excited to share our latest work on estimands in clinical trials!
📄 Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands.
🔗 Read the full paper: journals.sagepub.com/doi/10.1177/...
📄 Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands.
🔗 Read the full paper: journals.sagepub.com/doi/10.1177/...
🎓 Thinking about a PhD in clinical trial #methodology?
We have two funded PhD opportunities for students passionate about trial design and statistical methods:
• One in estimands
• One in non-inferiority trials
🔗 More info and how to apply here: buff.ly/lCpqcF6
@mrcnihrtmrp.bsky.social
We have two funded PhD opportunities for students passionate about trial design and statistical methods:
• One in estimands
• One in non-inferiority trials
🔗 More info and how to apply here: buff.ly/lCpqcF6
@mrcnihrtmrp.bsky.social
Current Opportunities
We have an iCASE studentship available to start for the 2025/2026 academic year, and applications to our fifth round of recruitment to our DTP to start in October 2026 are now also open. Please see…
buff.ly
October 23, 2025 at 9:02 AM
🎓 Thinking about a PhD in clinical trial #methodology?
We have two funded PhD opportunities for students passionate about trial design and statistical methods:
• One in estimands
• One in non-inferiority trials
🔗 More info and how to apply here: buff.ly/lCpqcF6
@mrcnihrtmrp.bsky.social
We have two funded PhD opportunities for students passionate about trial design and statistical methods:
• One in estimands
• One in non-inferiority trials
🔗 More info and how to apply here: buff.ly/lCpqcF6
@mrcnihrtmrp.bsky.social
Let’s kick off Wednesday with another #ProudestOf moment from our amazing team at the Unit!
Today, we’re spotlighting Paul Hyams, our Facilities, Health and Safety Manager at ICTM.
We asked Paul what he’s #ProudestOf in his work at the Unit 👇
Today, we’re spotlighting Paul Hyams, our Facilities, Health and Safety Manager at ICTM.
We asked Paul what he’s #ProudestOf in his work at the Unit 👇
October 22, 2025 at 7:09 AM
Let’s kick off Wednesday with another #ProudestOf moment from our amazing team at the Unit!
Today, we’re spotlighting Paul Hyams, our Facilities, Health and Safety Manager at ICTM.
We asked Paul what he’s #ProudestOf in his work at the Unit 👇
Today, we’re spotlighting Paul Hyams, our Facilities, Health and Safety Manager at ICTM.
We asked Paul what he’s #ProudestOf in his work at the Unit 👇
📈 Exciting news from #ESMO25!
First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery.
🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...
First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery.
🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...
A combination of two immunotherapy drugs benefits people with kidney cancer | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 21, 2025 at 8:15 AM
📈 Exciting news from #ESMO25!
First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery.
🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...
First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery.
🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...
Over the weekend, we announced new findings from the ICON8B trial at #ESMO25.
Results show that weekly chemotherapy with bevacizumab improves survival of women with advanced #OvarianCancer compared to having it once every 3 weeks.
🔗Learn more on our website: www.mrcctu.ucl.ac.uk/news/news-st...
Results show that weekly chemotherapy with bevacizumab improves survival of women with advanced #OvarianCancer compared to having it once every 3 weeks.
🔗Learn more on our website: www.mrcctu.ucl.ac.uk/news/news-st...
Weekly chemotherapy with bevacizumab improves ovarian cancer survival compared to having it once every three weeks | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 20, 2025 at 9:02 AM
Over the weekend, we announced new findings from the ICON8B trial at #ESMO25.
Results show that weekly chemotherapy with bevacizumab improves survival of women with advanced #OvarianCancer compared to having it once every 3 weeks.
🔗Learn more on our website: www.mrcctu.ucl.ac.uk/news/news-st...
Results show that weekly chemotherapy with bevacizumab improves survival of women with advanced #OvarianCancer compared to having it once every 3 weeks.
🔗Learn more on our website: www.mrcctu.ucl.ac.uk/news/news-st...
🚨Big news in Parkinson’s research!
We are excited to share that the largest-ever Parkinson’s disease trial has launched across the UK. Using our multi-arm, multi-stage #MAMS design, the #ejsactpd trial aims to stop or slow the progression of the disease.
🔗 More www.mrcctu.ucl.ac.uk/news/news-st...
We are excited to share that the largest-ever Parkinson’s disease trial has launched across the UK. Using our multi-arm, multi-stage #MAMS design, the #ejsactpd trial aims to stop or slow the progression of the disease.
🔗 More www.mrcctu.ucl.ac.uk/news/news-st...
Largest-ever Parkinson’s disease trial opens across UK | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 16, 2025 at 9:30 AM
🚨Big news in Parkinson’s research!
We are excited to share that the largest-ever Parkinson’s disease trial has launched across the UK. Using our multi-arm, multi-stage #MAMS design, the #ejsactpd trial aims to stop or slow the progression of the disease.
🔗 More www.mrcctu.ucl.ac.uk/news/news-st...
We are excited to share that the largest-ever Parkinson’s disease trial has launched across the UK. Using our multi-arm, multi-stage #MAMS design, the #ejsactpd trial aims to stop or slow the progression of the disease.
🔗 More www.mrcctu.ucl.ac.uk/news/news-st...
#ESMO25 is fast approaching…
If you are attending, check out the details of talks and posters featuring MRC CTU at UCL trials and meta-analysis work 👇
If you are attending, check out the details of talks and posters featuring MRC CTU at UCL trials and meta-analysis work 👇
Heading to #ESMO2025 in Berlin?
Make sure you catch the latest updates from our #ClinicalTrials in prostate, ovarian & kidney cancer, plus the STOPCAP meta-analysis.
Check out the full list of our posters & presentations in the image below 👇
@myesmo.bsky.social
Make sure you catch the latest updates from our #ClinicalTrials in prostate, ovarian & kidney cancer, plus the STOPCAP meta-analysis.
Check out the full list of our posters & presentations in the image below 👇
@myesmo.bsky.social
October 15, 2025 at 9:22 AM
#ESMO25 is fast approaching…
If you are attending, check out the details of talks and posters featuring MRC CTU at UCL trials and meta-analysis work 👇
If you are attending, check out the details of talks and posters featuring MRC CTU at UCL trials and meta-analysis work 👇
Wednesdays are our #ProudestOf days at the Unit!
This week, meet Berta Terre Torras, our Science Communications Officer and host of the #TrialTalk podcast.
We asked Berta what she’s #ProudestOf in his work at the Unit 👇
This week, meet Berta Terre Torras, our Science Communications Officer and host of the #TrialTalk podcast.
We asked Berta what she’s #ProudestOf in his work at the Unit 👇
October 15, 2025 at 8:32 AM
Wednesdays are our #ProudestOf days at the Unit!
This week, meet Berta Terre Torras, our Science Communications Officer and host of the #TrialTalk podcast.
We asked Berta what she’s #ProudestOf in his work at the Unit 👇
This week, meet Berta Terre Torras, our Science Communications Officer and host of the #TrialTalk podcast.
We asked Berta what she’s #ProudestOf in his work at the Unit 👇
To mark #BreastCancerAwarenessMonth, we are spotlighting the Add-Aspirin trial, which explores whether taking aspirin regularly after treatment could help stop breast cancer (and other cancers) from coming back.
🔗 Find out more about Add-Aspirin: www.mrcctu.ucl.ac.uk/studies/all-...
🔗 Find out more about Add-Aspirin: www.mrcctu.ucl.ac.uk/studies/all-...
Add-Aspirin | MRC Clinical Trials Unit at UCL
www.mrcctu.ucl.ac.uk
October 14, 2025 at 8:22 AM
To mark #BreastCancerAwarenessMonth, we are spotlighting the Add-Aspirin trial, which explores whether taking aspirin regularly after treatment could help stop breast cancer (and other cancers) from coming back.
🔗 Find out more about Add-Aspirin: www.mrcctu.ucl.ac.uk/studies/all-...
🔗 Find out more about Add-Aspirin: www.mrcctu.ucl.ac.uk/studies/all-...
Reposted by MRC Clinical Trials Unit at UCL
📊 Join this UCL @mrcctu.bsky.social Capacity Strengthening Hub webinar!
In collaboration with @lshtm.bsky.social 's ISEP team
🗓️ 13 Oct 2025 | ⏰ 10:00–11:30 UTC+1 | 💻 Online
🎙️ Speakers: Michelle Clements, Andrew Abaasa, Philip Ayieko, Vicky Simms
🔗 Register here: shorturl.at/hGtLq
In collaboration with @lshtm.bsky.social 's ISEP team
🗓️ 13 Oct 2025 | ⏰ 10:00–11:30 UTC+1 | 💻 Online
🎙️ Speakers: Michelle Clements, Andrew Abaasa, Philip Ayieko, Vicky Simms
🔗 Register here: shorturl.at/hGtLq
October 10, 2025 at 10:40 AM
📊 Join this UCL @mrcctu.bsky.social Capacity Strengthening Hub webinar!
In collaboration with @lshtm.bsky.social 's ISEP team
🗓️ 13 Oct 2025 | ⏰ 10:00–11:30 UTC+1 | 💻 Online
🎙️ Speakers: Michelle Clements, Andrew Abaasa, Philip Ayieko, Vicky Simms
🔗 Register here: shorturl.at/hGtLq
In collaboration with @lshtm.bsky.social 's ISEP team
🗓️ 13 Oct 2025 | ⏰ 10:00–11:30 UTC+1 | 💻 Online
🎙️ Speakers: Michelle Clements, Andrew Abaasa, Philip Ayieko, Vicky Simms
🔗 Register here: shorturl.at/hGtLq